Ads
related to: ceftriaxone for uti doseresearchverified.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Urinary tract infection in pediatric patients is a significant clinical issue, affecting approximately 7% of fevered infants and children. [43] If left untreated, the infection can ascend from the bladder to the kidneys, resulting in acute pyelonephritis, which leads to hypertension , kidney scarring , and end-stage kidney disease .
These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease. [5] For gonorrhea typically only one dose is required. [6] In the United States it is a second-line treatment to ceftriaxone for gonorrhea. [5] It is taken by mouth. [5] Common side effects include diarrhea, abdominal pain, and ...
Urinary tract infections, bacterial prostatitis, community-acquired pneumonia, bacterial diarrhea, mycoplasmal infections, gonorrhea: Nausea (rare), irreversible damage to central nervous system (uncommon), tendinosis (rare) Inhibits the bacterial DNA gyrase or the topoisomerase IV enzyme, thereby inhibiting DNA replication and transcription ...
A urinary tract infection (UTI) is an infection that affects a part of the urinary tract. [1] Lower urinary tract infections may involve the bladder ( cystitis ) or urethra ( urethritis ) while upper urinary tract infections affect the kidney ( pyelonephritis ). [ 10 ]
However, ceftriaxone has the advantage of once-daily dosing, whereas the shorter half-life of cefotaxime necessitates two or three daily doses for efficacy. Changing patterns in microbial resistance suggest cefotaxime may be suffering greater resistance than ceftriaxone, whereas the two were previously considered comparable. [15]